A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Solid Tumors and Advanced Gynecologic Cancers, With a Focus on Ovarian Cancer

Trial Profile

A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Solid Tumors and Advanced Gynecologic Cancers, With a Focus on Ovarian Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Rucaparib (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 03 May 2017 According to a Clovis Oncology media release, status changed from not yet recruiting to recruiting.
    • 03 Apr 2017 Status changed from planning to not yet recruiting.
    • 08 Aug 2016 According to a Clovis Oncology media release, this trial is expected to begin screening patients in the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top